VBIO Archives - BioTuesdays

Developments

Valion’s interim CEO Dean Zikria unveils 30-day agenda to advance pipeline and maximize shareholder value

Valion Bio (NASDAQ: VBIO) has shared the initial findings and priorities from Dean Zikria’s first 30 days as interim chief executive officer (CEO). Mr. Zikria’s strategic review has set a focused agenda built on three...

October 21, 2026

Developments

Valion’s next-gen NMR partnership with LarmorBio delivers initial feasibility milestone

Valion Bio (NASDAQ: VBIO) and closely held LarmorBio today announced that Velocity Bioworks, Valion’s wholly owned biologics contract development and manufacturing organization (CDMO) subsidiary, has successfully...

October 15, 2026

Developments

Valion’s Velocity Bioworks capitalizes on domestic CDMO surge amid Section 232 tariffs

Valion Bio (NASDAQ: VBIO) has highlighted the capabilities of its wholly owned contract development and manufacturing organization (CDMO), Velocity Bioworks. Velocity is part of Valion’s own domestic biologics...

October 14, 2026

Developments

As AI powers a U.S. nuclear buildout, Valion’s needle-free Entolimod could bring radiation preparedness to population scale

Rising electricity demand from AI and data centers is driving plans to expand nuclear power capacity, possibly including on-site small modular reactors (SMRs). This made international headlines earlier this week as...

October 9, 2026

Executive Moves

Valion board chair Thomas Jensen brings biotech turnaround experience to advance Entolimod

Valion Bio (NASDAQ: VBIO) has outlined the perspectives of its new board chair, Thomas H. Jensen, on advancing Entolimod—an investigational Toll-like receptor 5 (TLR5) agonist being developed as a potential medical...

October 5, 2026

Developments

Valion sees potential for multi-fold expansion of long-term opportunity after successful joint formulation of oral mucosal Entolimod for acute radiation syndrome

Valion Bio (NASDAQ: VBIO) and closely held Shear Kershman Laboratories (SKL) announced the successful completion of formulation work under the companies’ ongoing program to develop a novel oral mucosal formulation of...

September 30, 2026

Executive Moves

Valion appoints life sciences veteran Dean Zikria as interim CEO and announces board leadership transitions

Valion Bio (NASDAQ: VBIO) has announced the appointment of Dean Zikria as interim CEO, along with leadership changes aimed at strengthening alignment and execution as it advances Entolimod and evaluates strategic...

September 24, 2026

Executive Moves

Valion announces changes to management and BOD

Valion Bio (NASDAQ: VBIO) has announced that its current chief financial officer, Lisa Wolf, has also been named president and chief operating officer, effective immediately, following the departure of former chief...

September 1, 2026

Developments

Valion announces U.S. government-funded Entolimod studies targeting lethal radiation-induced GI injury

Valion Bio (NASDAQ: VBIO) has announced that the Armed Forces Radiobiology Research Institute (AFRRI), under its contract with the National Institute of Allergy and Infectious Diseases, is conducting a U.S. Department...

August 12, 2026

Developments

Ukraine MoH Accepts Valion Bio’s Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway

Valion Bio (NASDAQ: VBIO) has announced that the regulatory dossier for its lead candidate, Entolimod for acute radiation syndrome (ARS), has been accepted by Ukraine’s Ministry of Health (MoH) for formal review...

July 22, 2026

Tag - VBIO

Valion’s interim CEO Dean Zikria unveils 30-day agenda to advance pipeline and maximize shareholder value

Valion’s next-gen NMR partnership with LarmorBio delivers initial feasibility milestone

Valion’s Velocity Bioworks capitalizes on domestic CDMO surge amid Section 232 tariffs

As AI powers a U.S. nuclear buildout, Valion’s needle-free Entolimod could bring radiation preparedness to population scale

Valion board chair Thomas Jensen brings biotech turnaround experience to advance Entolimod

Valion sees potential for multi-fold expansion of long-term opportunity after successful joint formulation of oral mucosal Entolimod for acute radiation syndrome

Valion appoints life sciences veteran Dean Zikria as interim CEO and announces board leadership transitions

Valion announces changes to management and BOD

Valion announces U.S. government-funded Entolimod studies targeting lethal radiation-induced GI injury

Ukraine MoH Accepts Valion Bio’s Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway

Subscribe